US/UK/Canada

Share

Contacts

  • General Press Enquiries
    For general press enquiries please contact the AbbVie Corporate Communications team at UKMediaRelations@abbvie.com or call us on 01628 925200
    01628 925200
    https://twitter.com/abbvieuk
    • Pick a time period -

    AbbVie UK Publishes 2019 Transparency Data; Supporting Collaboration of Medical Opinion Towards Advancing Patient Care and the Development of New Medicines

    Maidenhead, UK, 30 June 2020 – Each year AbbVie discloses individual and aggregated transfers of value to healthcare professionals (HCPs) and healthcare organisations (HCOs) to the Association of the British Pharmaceutical Industry (ABPI). Due to the unprecedented demands on the NHS as a result of the COVID-19 pandemic, the ABPI provided guidance to companies to submit only their aggregated transfers of value data for 2019 for publication on its central platform, Disclosure UK, and to publish their disaggregated data on their company websites. AbbVie has adopted this guidance and our

    New VENCLYXTO®▼(venetoclax) Data Demonstrate Utility Across Acute Myeloid Leukaemia (AML) Patients and Chronic Lymphocytic Leukaemia (CLL)

    · Phase III VIALE-A study showed a 34% reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared with azacitidine plus placebo[1] · Patients in the venetoclax arm showed improved median overall survival (14.7 months) versus azacitidine alone (9.6 months) and improved rate of composite complete remission (CR + CRi) (66.4%) versus those treated with azacitidine alone (28.3%)[1] · Notable data in CLL patients include Phase III results from the CLL14 trial[2] and Phase III sub-analysis from the

    AbbVie Presents New Late-Breaking Data Showing SKYRIZI▼® (risankizumab) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks

    -New head-to-head data from the IMMerge Phase 3b open-label study show SKYRIZI demonstrated superiority to COSENTYX at week 52, with 66percent of SKYRIZI patients achieving completely clear skin (PASI100) versus 40 percent of COSENTYX patients[1] -No new safety signals were observed for SKYRIZI through 52 weeks[1] -Results presented at the American Academy of Dermatology virtual annual meeting MAIDENHEAD, UK, June 12, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior rates of

    New Long-term Data from RINVOQ® ▼(upadacitinib). Phase 3 Studies in Rheumatoid Arthritis Presented at Annual European E-Congress of Rheumatology (EULAR)

    · Long-term results from the SELECT-COMPARE and SELECT-MONOTHERAPY studies showed that upadacitinib continued to improve signs and symptoms in patients with rheumatoid arthritis through 72 and 84 weeks, respectively[1,2] · Results from SELECT-EARLY and SELECT-COMPARE showed upadacitinib inhibited structural joint damage in rheumatoid arthritis patients receiving upadacitinib as monotherapy or in combination with MTX at almost two years[3] · Upadacitinib’s safety profile was consistent across the pivotal Phase 3 programme, with no new safety signals identified[1-5] MAIDENHEAD, UK,

    AbbVie host shared decision making showcase in Parliament to highlight importance of patients being involved in decisions about their care

    MAIDENHEAD, UK, 10[th] March, 2020 AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today hosted a Showcase on Shared Decision Making, which highlighted the importance of patients being involved in decisions made about their care. The showcase took place just over one year after the launch of the NHS Long Term Plan and Universal Personalised Care Plan which established ambitious targets to put shared decision making at the heart of patient care. The showcase provided a platform for patient groups, NHS Trusts, and healthcare providers to share their innovative

    New Head-to-Head Phase 3 Data Show SKYRIZI▼™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks

    -Risankizumab met both primary and all secondary endpoints in a head-to-head, open-label study versus secukinumab[1] -Of patients treated with risankizumab, 87 percent achieved PASI 90 compared to 57 percent of secukinumab-treated patients at 52 weeks (p<0.001)[1] -No new safety signals were observed[1] MAIDENHEAD, January 14, 2020– AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI▼(risankizumab) met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx (secukinumab) in a head-to-head

    RINVOQ® ▼(upadacitinib) Granted EU Marketing Authorisation for the Treatment of Eligible Adults with Moderate to Severe Active Rheumatoid Arthritis

    · Marketing authorisation supported by data from the pivotal Phase 3 SELECT rheumatoid arthritis programme evaluating nearly 4,400 patients[1-5] · In five pivotal Phase 3 studies, upadacitinib met all primary and ranked secondary endpoints across a variety of adult patient populations with moderate to severe active rheumatoid arthritis[1-5] · Upadacitinib offered patients improved rates of clinical remission* or low disease activity** compared to treatment with placebo; methotrexate monotherapy; and adalimumab plus methotrexate [1-5] · An estimated 400,000 people in the UK are

    AbbVie Presents New Long-Term Data From VENCLYXTO®▼ (venetoclax) Chemotherapy-Free Combination Regimen in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

    · Four-year updated analysis from the MURANO trial showed an 81% reduction in the risk of disease progression or death in patients treated with venetoclax plus rituximab (VenR) and higher rates of undetectable minimal residual disease (uMRD) compared to bendamustine plus rituximab(BR)1 · Sustained overall survival (OS) benefit was demonstrated with VenR over BR (with a hazard ratio of 0.41), despite 79% of patients in the BR arm who went on to receive a novel targeted treatment. Median OS was not reached for either treatment group1 · 68% of the 130 patients who completed the

    AbbVie UK Announces Collaboration With NorthWest EHealth to Generate Real World Evidence to Drive Improvements in Patient Care

    · AbbVie and NorthWest EHealth intend to explore the underlying associations between autoimmune conditions, using technology to interrogate data from NHS general practices · Greater Manchester’s population makes the region the ideal location to conduct the work · This project is an example of the partnership approach envisaged by the UK Government’s Life Sciences Industrial Strategy, which stresses the importance of collaboration to generate real-world data MAIDENHEAD, UK, 27 November, 2019 – AbbVie, a research-based global biopharmaceutical company, together with NorthWest EHealth,

    AbbVie’s SKYRIZI™▼(risankizumab) accepted for use within NHS Scotland

    – Positive SMC Detailed Advice Document (DAD)[1] for SKYRIZI™ (risankizumab) - Adult patients in Scotland with plaque psoriasis who have failed, are intolerant to, or contraindicated to conventional systemic therapies, will have NHS access to treatment with high rate of skin clearance at 16 weeks that is maintained through to one year (52 weeks)[2] – SMC recommendation based on results from four pivotal Phase 3 studies, UltIMMa-1, UltIMMa-2, IMMvent and IMMhance evaluating more than 2,000 patients with moderate to severe plaque psoriasis[2-5] – Plaque psoriasis is a chronic

    SKYRIZI™▼(risankizumab) Receives NICE Positive Technology Appraisal Guidance for the Treatment of Plaque Psoriasis in Adults

    MAIDENHEAD, UK, 21 August 2019 - AbbVie (NYSE: ABBV), a research-based biopharmaceutical company, announces that eligible patients in England and Wales with plaque psoriasis who have failed conventional systemic therapies will have access to SKYRIZI™▼(risankizumab) following the issuing by the National Institute for Health and Care Excellence (NICE) of the Technology Appraisal Guidance (TAG) recommending the treatment[1]. The TAG represents the completion of the final step of NICE assessment and follows a positive recommendation by NICE through its Fast Track Appraisal process, which has

    New chemotherapy-free combination treatment VENCLYXTO®▼(venetoclax) plus rituximab accepted for use on the NHS in Scotland for people with previously treated Chronic Lymphocytic Leukaemia

    · For the first time, people in Scotland with Chronic Lymphocytic Leukaemia (CLL), who have received at least one prior therapy, now have access to a new chemotherapy-free option with a fixed treatment duration of 24 months.[1] · SMC acceptance is based on the MURANO phase 3 clinical trial, in which venetoclax plus rituximab (VenR) reduced the risk of disease progression or death by eighty-three percent compared to a standard of care chemoimmunotherapy regimen of bendamustine plus rituximab (BR).[1] · CLL is the most common form of adult leukaemia with over 3,500 people diagnosed

    Results From SKYRIZI™ ▼ (risankizumab) Phase 3 Study in Moderate to Severe Plaque Psoriasis Published in The Lancet

    · In the IMMvent study, 72 percent and 84 percent of patients treated with SKYRIZI™ (risankizumab) achieved PASI 90 and sPGA 0/1, respectively, at week 16 [i] Maidenhead, UK, 24 July 2019 — AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the publication of positive results from the pivotal Phase 3 IMMvent clinical study in The Lancet. The study evaluates the safety and efficacy of SKYRIZI™▼ (risankizumab) up to 44 weeks compared to adalimumab in adult patients with moderate to severe chronic plaque psoriasis.[1] Risankizumab met the co-primary

    AbbVie Appoints New General Manager in U.K.

    Maidenhead, UK, 19th July 2019 – AbbVie, a global biopharmaceutical company, today announced that Todd Manning has been named General Manager, AbbVie U.K. This change will be effective 1st September 2019. Todd moves to the UK from his current position within the company as General Manager, AbbVie Ireland. Elected to the Irish Pharmaceutical Healthcare Association (IPHA) strategy board in 2016 and to the Board of Directors in 2018, he has held the positions of Deputy Vice President and Chair of the Finance Committee. He also served on several working groups including Market Access and

    NICE Issues Positive Final Appraisal Document for SKYRIZI™▼(risankizumab) for the Treatment of Plaque Psoriasis in Adults

    – Positive NICE Final Appraisal Document (FAD) for SKYRIZI™ (risankizumab), a humanised immunoglobulin G1 (IgG1) monoclonal antibody, means that adult patients in England and Wales with plaque psoriasis, who have failed conventional systemic therapies, will have NHS access to treatment with high rate of skin clearance at 16 weeks that is maintained through to one year (52 weeks)[1] - Risankizumab has been reviewed by NICE through its Fast Track Appraisal process, meaning that NHS England/commissioners have committed to providing funding for risankizumab within 30 days of final guidance

    Results from Upadacitinib Phase 3 SELECT-COMPARE Study Published in Arthritis and Rheumatology

    · SELECT-COMPARE, the largest of the six studies in the robust SELECT programme, evaluates upadacitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate (MTX), and remain on a stable background of MTX[1] · Both primary endpoints of the study were met, including the proportion of patients achieving ACR20 response and clinical remission (DAS28-CRP<2.6) at week 12 for upadacitinib versus placebo[1] · No new safety signals were reported compared to previously reported Phase 3 studies[1-5] · Upadacitinib, an oral

    AbbVie UK publishes 2018 transparency data; supporting collaboration of medical opinion towards advancing patient care and the development of new medicines

    Maidenhead, UK, 28th June 2019 – For the fourth year, AbbVie is pleased to see a rise in the number of doctors willing to consent to their transfers of value being made public. Each year AbbVie discloses transfers of value to healthcare professionals and healthcare organisations to the Association of the British Pharmaceutical Industry (ABPI). 79 per cent (Nearly 4 in 5) of doctors who received sponsorship, fees or ‘in-kind’ support from AbbVie in 2018 opted-in for their individual data to be made public in the scheme. AbbVie is encouraged that this marks increased confidence in

    New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ ▼(risankizumab) Maintains Complete Skin Clearance in a Significant Number of Patients

    · The co-primary and secondary endpoints for the IMMhance study were met · Longer-term results from IMMhance in additional analyses showed 73 percent and 72 percent of patients treated with continuous risankizumab experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28[1] · No new safety findings observed at two years (104 weeks)[1][] · Risankizumab, a humanised immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit, is approved by the

    AbbVie Presents Data from VENCLYXTO®▼(venetoclax) Chemotherapy-Free Combination Regimen for Patients with Previously Untreated Chronic Lymphocytic

    · Phase 3 CLL14 data were highlighted in an oral presentation (abstract #7502) today at ASCO and published in the New England Journal of Medicine · Patients treated with venetoclax plus obinutuzumab lived significantly longer without their disease progressing, and sustained that benefit after stopping treatment, compared to those treated with obinutuzumab plus chlorambucil · Rates of undetectable minimal residual disease* in peripheral blood were higher in patients treated with venetoclax plus obinutuzumab three months after treatment completion[1] MAIDENHEAD, UK, 4 June, 2019 –

    Results from Upadacitinib Phase 3 SELECT-MONOTHERAPY Study Published in The Lancet

    · SELECT-MONOTHERAPY evaluates the safety and efficacy of upadacitinib monotherapy in adult patients with moderately to severely active rheumatoid arthritis and inadequate response to a stable dose of methotrexate[1] · Upadacitinib (15 mg and 30 mg), once daily, achieved both primary endpoints with significantly higher rates of ACR20 response and low disease activity (defined as DAS28[CRP]≤3.2) at week 14 versus continued treatment with methotrexate[1] · Patients receiving either dose of upadacitinib monotherapy also achieved significantly higher rates of clinical remission (

    SKYRIZI™ ▼(risankizumab) Granted EU Marketing Authorisation for the Treatment of Moderate to Severe Plaque Psoriasis in Adults

    – Authorisation based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was also observed at one year with every 12-week maintenance dosing1-4 – Risankizumab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit, offers moderate to severe psoriasis patients a new therapeutic option5 – Psoriasis is a chronic condition affecting 125 million people worldwide and many patients still do not reach treatment goals or lose treatment response over time6-8 MAIDENHEAD, UK,

    ABBVIE STATEMENT ON NHS ENGLAND CONTRACT AWARD IN HEPATITIS C ELIMINATION TENDER

    EMBARGOED UNTIL 00.01 TUESDAY 30 APRIL MAIDENHEAD, UK, 30 April, 2019 –AbbVie welcomes the award of a contract by NHS England to continue working in partnership to facilitate the identification and treatment of hepatitis C (HCV) patients in England. This is an important step towards bringing closer the goal of NHS England (NHSE) to eliminate hepatitis C in England by 2025. “Our aim to bring well-tolerated, highly effective and curative treatments to patients that need them, and to eliminate this chronic disease as a burden to the healthcare system, is today closer to being achieved,”

    AbbVie Receives CHMP Positive Opinion for SKYRIZI™ ▼ (risankizumab) for the Treatment of Moderate to Severe Plaque Psoriasis in adults

    –CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission[1-3] –In Phase 3 trials, risankizumab achieved significantly greater response of clear or almost clear skin (sPGA 0/1 and PASI 90) compared to ustekinumab, adalimumab and placebo at week 16 and up to week 52 with every 12-week dosing after initial start dosing[1-3] –Risankizumab (under the trade name SKYRIZI) is an investigational, humanized immunoglobulin G1 (IgG1) monoclonal antibody

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media